Solara Active Pharma Sciences Announces Second & Final Call of ₹112.50 Per Share
Solara Active Pharma Sciences' Rights Issue Committee approved a Second & Final Call of ₹112.50 per equity share for partly-paid Rights Shares. The call, comprising ₹3 face value and ₹109.50 premium, is made under the May 09, 2024 Letter of Offer. April 02, 2026, is fixed as the Record Date for call notices.
This is a follow-up action on a previously completed rights issue. The call amount is a procedural step to collect the remaining payment for shares already allocated, and does not represent new fundraising or a significant change in the company's financial structure.
The announcement is a routine procedural step related to a past rights issue, involving a call for payment on partly-paid shares. It does not inherently introduce new positive or negative financial performance or strategic shifts.
Solara Active Pharma Sciences Limited has announced the outcome of its Rights Issue Committee Meeting held on March 24, 2026. The committee approved the making of the Second & Final Call of ₹112.50 per equity share for partly-paid Rights Shares. This amount includes ₹3.00 towards face value and ₹109.50 towards securities premium.
The call is being made pursuant to the Letter of Offer dated May 09, 2024. The Rights Issue Committee has fixed Thursday, April 02, 2026, as the Record Date. This date will be used to determine the holders of partly paid-up Equity Shares who will receive the call notice for payment of the call.
The meeting of the Rights Issue Committee commenced at 9:30 A.M. and concluded at 9:55 A.M. on March 24, 2026. The company has confirmed that there are no applicable details regarding forfeiture of shares, reissue of forfeited shares, proposal to issue any class of securities, or changes in terms regarding redemption/cancellation/retirement of securities.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under debt fundraising. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.